Kornimate/medical-research-clean huggingface dataset:
effect of wearable hip-assist robot on reduction of cardiopulmonary metabolic efficiency in healthy adults

Conditions: Gait

Summary: the purpose of this study was to investigate the changes in muscle fatigue and respiratory metabolic energy expenditure during walking with wearable hip-assist robot (v3).

the purpose of this study was to investigate the changes in muscle fatigue and respiratory metabolic energy expenditure during walking with wearable hip-assist robot (v3). metabolic energy expenditure and muscle fatigue are measured simultaneously.

Eligibility criteria:
inclusion criteria: * elderly adults over age 65 * those without a history of central nervous system disease exclusion criteria: * those who have problems with walking due to problems such as visual field defects or fractures * a person whose height is less than 140 cm or not more than 185 cm * body mass index bmi (body mass index) based on 35 or more obese * those with a cognitive problem that are difficult to understand and participate fully in this study * those who are at risk of falling when walking with serious dizziness

Keywords: muscle; fatigue wearable hip assist robot metabolic energy expenditure
a study to determine the effects of tm30339 on weight loss in obese individuals.

Conditions: Obesity

Summary: the purpose of this study is to determine the effects of tm30339 on weight loss in obese individuals after 28 days dosing.

obesity is a disease with large socioeconomic consequences and many serious health consequences including type 2 diabetes, dyslipidemia and cardiovascular diseases. the prevalence of obesity is increasing both in developed and developing countries. there is a great need for further medicinal treatments that effectively will support life style changes or surgical procedures in reducing or maintaining bodyweight. 7tm pharma has identified tm30339 as a clinical development candidate molecule with potential to assist in the control and amelioration of obesity in humans.

Eligibility criteria:
inclusion criteria: 1. obese males and females with a bmi of 30-40 kg/m2 inclusive and weight in the range of 85 - 135 kg inclusive 2. age 18-60 years inclusive 3. stable lifestyle e.g. smoking, exercise and eating patterns and times for at least 6 months, and willing to maintain these habits during the course of the study 4. stable weight over past 2 months i.e. a change in body weight \< 3 kg as reported by the subject exclusion criteria: 1. subjects with a history of allergies toward products containing natural rubber (e.g. latex) 2. subjects with, or with a history of, any clinically significant neurological, gastrointestinal (including bariatric surgery), renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, or other major disorders 3. subjects who have a supine blood pressure at screening or visit 1 higher than 150/95 mmhg by repeat measurements within 15 minutes 4. subjects who have a qtc (bazett's correction) interval of \> 450 msec at screening 5. subjects with bradycardia (heart rate \< 50) 6. subjects with heart block 7. clinically significant thyroid dysfunction as evidenced by tsh \> 1.5 x uln

Keywords: obesity weight loss 7tm pharma tm30339 y4 receptor antagonist
analysis of in vitro biological reaction of diaphragmatic prothesis when congenital diaphragmatic hernia (cdh) repair

Conditions: Congenital Diaphragmatic Repair

Summary: in case of cdh, the incomplete development of a part of the diaphragm allows abdominal viscera to herniate into thorax cavity during fetal development and impaired lung and heart development. after birth, cdh patients who survived thanks to an active reanimation management undergo diaphragmatic repair. in case of large defect, a patch is needed to complete diaphragmatic closure. thanks to primary cell culture from foreskin, peritoneal epithelium or cremaster dedicated to incineration investigators want to analyse biological integration of actually used prothesis and others innovations.


Eligibility criteria:
inclusion criteria: * minor aged 0 (day of birth) to 14 years * patient for whom an indication of posthectomy and / or cure of inguinal hernia and / or testicular ectopy is retained * patient whose legal representatives have agreed to the use of operational waste from mesenchymal tissues (foreskin, cremaster and peritoneum) destined for incineration. * patient affiliated to a social security scheme exclusion criteria: - parents don't agree to the use of its operating waste for research purposes
metformin effects on oxidative stress parameters in newly diagnosed type 2 diabetes patients

Conditions: Type 2 Diabetes Mellitus

Summary: oxidative stress plays a key role in the pathogenesis of diabetes complications. chronic hyperglycemia and disturbed lipid regulation commonly seen in diabetes are the main causes of this process. despite the critical role of oxidative stress in diabetes, most clinical trials with available antioxidants and vitamins have either failed to show any long term benefits or have produced inconsistent results (10-11). there has been growing interest in establishing the possible roles of oral hypoglycemic agents including metformin in reduction of oxidative stress. metformin, the most common prescribed oral medication in type 2 diabetes, lowers hba1c around 1.5%, rarely causes hypoglycemia (compared with insulin or sulfonylureas), has relatively few contraindications, its adverse effects are generally tolerable, does not cause weight gain, is cheap, and is highly acceptable among patients. given the long term benefits observed with metformin use, a role in modulating oxidative stress is imputable. we designed this study to evaluate the actions of metformin on oxidative stress in a group of medication-naïve newly diagnosed type 2 diabetes patients.


Eligibility criteria:
inclusion criteria: * newly diagnosed type 2 diabetes patients based on american diabetes association criteria for diagnosis of diabetes exclusion criteria: * no history of serious chronic illnesses of heart, lung, and kidney * no prior treatment with anti-diabetes medications for either diabetes or conditions associated with hyperglycemia * no intake of prescribed or over-the-counter vitamins c and e in the past year; - no intake of aspirin in the past year * no history of excessive alcohol intake in the past year
movement analysis of stroke patients when walking on a treadmill

Conditions: Stroke

Summary: in daily clinic, the use of treadmills to analyze the gait quality of a patient increases. the advantages of using a treadmill are that a smaller space is needed compared to a 3d lab for motion analysis, more steps can be recorded in shorter time period and patients should not start, stop or rotate during the analyses. one of the systems which can be used to perform motion analysis on a treadmill is the grail. this grail (gait real-time analysis interactive lab) consists of an advanced treadmill with force sensors. patients can walk on this treadmill with an imposed speed (fixed-speed) or at a speed determined by the patient itself (self-paced). because not everyone is used to walk on a treadmill it is important to know if a person's walking pattern is different when he walks over ground compared to walking on the treadmill. based on these insights, decisions can be made regarding interventions including treadmill training or this findings can be taking into account during further analysis of walking patterns on a treadmill. for this study stroke patients would be invited for an assessment on the treadmill (1 assessment moment). the movement pattern of these patients would be compared in different conditions: * (forward and backward) walking at comfortable walking speed on the gaitrite * walking at comfortable walking speed on the treadmill in fixed speed mode * walking at comfortable walking speed +0.2 m/s (faster walking) on the treadmill in fixed speed mode * walking at comfortable walking speed on the treadmill in self-paced mode * backward walking at comfortable walking speed on the treadmill in fixed speed mode (only if patients are eligible to do so) hypotheses based on this study protocol: * do stroke patients walk different over ground compared to treadmill walking * do stroke patients walk different during treadmill walking self-paced compared to fixed speed * do stroke patients walk different during treadmill walking fixed speed comfortable walking speed compared to fast walking * is there a correlation between upper extremity impairment and arm swing


Eligibility criteria:
inclusion criteria: * stroke patients with the ability to walk without walking devices for 6 minutes without rest (indoor walking). use of afo is allowed if necessary. exclusion criteria: * traumatic brain lesions (car accident, fall with bike, ...) * other disorders such as neurologic, musculoskeletal, respiratory or severe cardiovascular disorders that affected gait performance * bilateral stroke * cerebellar stroke * orthopedic surgery lower limbs in the past * cognitive or language impairments that prevent the patients from understand simple orders

Keywords: gait pattern treadmill walking arm swing
comparison of therapeutic effects between intravitreal injection of bevacizumab with intravitreal injection of bevacizumab and targeted laser photocoagulation of non perfused areas of retina in patients with acute retinal vein occlusion

Conditions: Retinal Vein Occlusion With Macular Edema

Summary: patients with new onset retinal vein occlusion in less than 3 month whom has visual acuity less than 20/40 and central macular thickness more than 250micrometer and non perfused areas of retina more than 10 dd are included in over study and devided into 2 groups randomizely, group a under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for visual acuity and central macular thickness, if in month four or more the cmt is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeated and follow up in this manner is continued until 9 months. group b is as the same of group a but patients in this group undergone laser photocoagulation of retinal non perfused areas based on fag wide field imaging . after 9 month follow up the outcomes such as vusal acuity, central macular thickness, intraocular pressure, neovascular formation are compared,


Eligibility criteria:
inclusion criteria: * center-involved macular edema secondary to rvo on clinical exam * symptoms less than 3 months * bcva= 20/40 or worse * mean center point thickness \>250 μm * media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs one eye per participant is enrolled in the trial exclusion criteria: * macular edema due to a cause other than crvo * an ocular condition such that visual acuity would not improve from resolution of the edema (eg, foveal atrophy) * substantial cataract estimated to have reduced visual acuity by \>3 lines * prior treatment with intravitreal or peribulbar steroid injection * history of macular photocoagulation or prp * prior pars plana vitrectomy * hx of intraocular surgery (including cataract extraction) * uveitis, nvg, exudative amd, diabetic retinopathy, any malignancy, optic neuropathy, amblyopia * vitreomacular traction or epiretinal membrane \*uncontrolled glaucoma ( \> 30mmhg with anti-glaucoma medications)
a real-world study of herombopag in the treatment of thrombocytopenia related diseases in henan province

Conditions: Carcinoma;Blood

Summary: to observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in henan province

this study is designed as a real-world study on the treatment of thrombocytopenia-related diseases with herombopag, to observe and analyze the safety and efficacy of herombopag for thrombocytopenia-related diseases in the real world.

Eligibility criteria:
inclusion criteria: 1. thrombocytopenia related diseases; 2. volunteer to join this study and sign an informed consent form; 3. clinical evaluation can benefit from herombopag. exclusion criteria: 1. those who have been confirmed to be allergic to herombopag and/or its excipients; 2. pregnant or breastfeeding women; 3. except for patients with contraindications to herombopag; 4. doctors evaluate patients who are not suitable for inclusion.
a study of tabalumab (ly2127399) in participants with previously treated multiple myeloma (mm)

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate an investigational drug called tabalumab in participants with multiple myeloma (mm) who have tried at least one other therapy in the past. tabalumab will be given in combination with standard doses of two other drugs that are often used to treat mm. study doctors will collect information about the effectiveness and side effects of this therapy.


Eligibility criteria:
inclusion criteria: * have symptomatic and/or progressive mm that was previously treated with at least 1 and no more than 3 prior lines of therapy * have measurable disease * have given written informed consent prior to any study-specific procedures * have adequate organ function * treatment with prior autologous transplant is permitted exclusion criteria: * are enrolled in or discontinued from a clinical trial of any drug or device within 21 days prior to the first dose of assigned study treatment * have had less than a minimal response or have had progressive disease within 60 days of most recent therapy with a proteasome inhibitor * plan to proceed to autologous transplant for consolidation after participation in this trial * have an active infection or ongoing treatment for systemic infection ("ongoing treatment" does not include prophylactic anti-infectives),, chest x-ray suggestive of tuberculosis, or history/risk of chronic/latent infection that may reactivate in the presence of study therapy * have any of the following: * positive test results for human immunodeficiency virus (hiv) * positive test for hepatitis b, defined as positive for hepatitis b surface antigen (hbsag+), or positive for anti-hepatitis b core antibody and positive for hepatitis b deoxyribonucleic acid (hbv dna), or positive for anti-hepatitis b surface antibody (hbsab+) and positive for hepatitis b deoxyribonucleic acid (hbv dna) * positive test results for hepatitis c virus (hcv), defined as positive for hepatitis c antibody (hepcab) and confirmed positive via the hepatitis c recombinant immunoblot assay * have had significant allergy to human/humanized monoclonal antibodies that, in the opinion of the investigator, poses an unacceptable risk to the participants * have known hypersensitivity or contraindication to any of the study therapies or excipients * prior allogeneic hematopoietic stem cell transplant * prior therapy with experimental agents targeting b-cell activating factor (baff), including ly2127399 * have corrected qt (qtc) interval \>500 millisecond (msec) on baseline 12-lead electrocardiogram (ecg) * have waldenstrom's macroglobulinemia * history of malignancy with adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer, are eligible regardless of the time of diagnosis/treatment
reflexology or aromatherapy massage in relieving symptoms in patients with cancer

Conditions: Pain; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: reflexology and aromatherapy massage may lessen symptoms in patients with cancer. it is not yet known whether reflexology is more effective than aromatherapy massage in relieving symptoms in patients with cancer. purpose: this randomized clinical trial is studying reflexology to see how well it works compared with aromatherapy massage in relieving symptoms in patients with cancer.

objectives: primary * to determine whether reflexology is as effective as aromatherapy massage for alleviation of self-selected symptoms in patients with cancer in an outpatient setting. secondary * to determine the difference between the two therapies with respect to visual analogue scale (vas) relaxation scores before and after each treatment. outline: patients are stratified according to gender (male vs female), treatment (chemotherapy vs other) and their first concern choice (pain vs other). patients are randomized to 1 of 2 intervention arms. * arm i (reflexology): patients undergo 45-60 minutes of reflexology for 4 sessions. * arm ii (aromatherapy massage): patients undergo 45-60 minutes of of aromatherapy massage for 4 sessions. patients complete questionnaires (measure yourself concerns and well-being \[mycaw\] questionnaire and visual analogue scale \[vas\]) at baseline, before and after each session, and after completion of all four sessions.

Eligibility criteria:
disease characteristics: * any patient receiving treatment for cancer at the royal marsden nhs foundation trust hospital * must be attending the hospital as an outpatient * planning to access complementary therapy patient characteristics: * no excessive pain in both hands and both feet * not experiencing a combination of conditions affecting both hands and both feet which would prevent reflexology of either hands or feet from taking place, including any of the following: * deep vein thrombosis * lymphedema * infected or broken skin * recent scars or injuries * phlebitis * areas currently receiving radiotherapy (or received radiotherapy in the past 2 weeks) * able and willing to attend the hospital for four 1-hour sessions prior concurrent therapy: * see disease characteristics * at least 2 months since prior and no other concurrent massage therapy or reflexology at the royal marsden nhs foundation trust hospital or from another practitioner * not planning to undergo massage therapy or reflexology while also taking part in this study * at least 2 months since prior and no other concurrent massage therapy at the royal marsden nhs foundation trust hospital

Keywords: psychosocial effects of cancer and its treatment pain unspecified adult solid tumor, protocol specific
a study to evaluate the efficacy and safety of icotrokinra (jnj-77242113) in biologic-experienced participants with active psoriatic arthritis

Conditions: Arthritis, Psoriatic

Summary: the purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (psa) by assessing the reduction in signs and symptoms of psa.


Eligibility criteria:
inclusion criteria: * participants must have been previously treated with 1 biologic agent for psoriatic arthritis (psa) or psoriasis and the reason for discontinuation must be documented * have a diagnosis of psoriatic arthritis (psa) for at least 3 months before the first administration of study intervention and meet classification criteria for psoriatic arthritis (caspar) at screening * have active psa as defined by: (a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) c-reactive protein (crp) greater than or equal to (\>=) 0.1 milligrams per deciliter (mg/dl) at screening from the central laboratory. * have at least 1 of the psa subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis * have active plaque psoriasis with at least one psoriatic plaque of \>= 2 cm diameter or nail changes consistent with psoriasis * a female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hcg) at screening and a negative urine pregnancy test at week 0 prior to administration of study intervention exclusion criteria: * has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of psa), psychiatric, genitourinary, or metabolic disturbances * currently has a malignancy or has a history of malignancy within 5 years prior to screening * has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients * has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (ra), systemic lupus erythematosus, or lyme disease * participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments
rapid and easy evaluation of cardiac systolic function by means of mitral valve movements in the emergency department

Conditions: Heart; Disease, Mitral(Valve)

Summary: left ventricular ejection fraction (lvef) is a parameter that should be evaluated rapidly to the patients, admitted to the emergency department with shortness of breath. the investigators aimed to investigate correlation between lvef and 4 different mitral valve movements which alternate to the classical lvef assessing methods and evaluate these methods can be used or not in the emergency department.

a prospective observational study was conducted in an acutely dyspneic patients with receiving echocardiagraphy by the chief physicians. measurements were performed before echocardiography lab by the physician who conducted the survey in the emergency department. in parasternal long axis view mitral valve e-point septal separation (epss) m-mod measurements and mitral valve anterior leaflet and septal distance (p-alss) b-mod measurements and in apical four chamber view mitral valve anterior leaflet and septal distance (a-alss) b-mod measurements and distance between mitral valve anterior and posterior leaflets (mvls) b-mod measurements were acquired as the minimum distance in diastole. lvef of patients were measured by cardiologist. correlation of the all values between lvef and sensitivity, specificity, and likelihood probabilities were calculated.

Eligibility criteria:
inclusion criteria: * older than 18 years * nontraumatic acute dyspneic patients exclusion criteria: * sigmoid septum * septal hypertrophia * mitral stenosis * mitral valve prothesis * aortic regurgitation * regional wall motion defect

Keywords: ejection fraction mitral valve e-point septal separation
cotransplantation of islet and mesenchymal stem cell in type 1 diabetic patients

Conditions: Type 1 Diabetes Mellitus

Summary: the study evaluates the safety and efficacy of cotransplantation of islet and mesenchymal stem cell in type 1 diabetic patients. the researchers hypothesize that additional mesenchymal stem cell infusion can benefit the promising clinical islet transplantation through the following mechanisms: protection of islet from inflammatory damage, immunological modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin and improve β-cell function.


Eligibility criteria:
inclusion criteria: * male and female patients age 18 to 60 years of age * ability to provide written informed consent * manifest signs and symptoms that are severe enough to be incapacitating * patients with poor diabetes control (hba1c \> 7% but \< 12%) * progressive diabetic complications exclusion criteria: * age \ 60 years * diabetic history \< 5 years * bmi \> 27 * body weight \> 80 kg * exogenous insulin requirement \> 1 unit/kg/day * severe anemia (male \< 8 g/dl, female \< 7 g/dl) * low white blood cell count (\< 3000/dl) * liver dysfunction * active infection including hepatitis b, hepatitis c, hiv, or tb * panel reactive antibody \> 20% * any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial

Keywords: islets of langerhans transplantation mesenchymal stem cells type 1 diabetes mellitus